Welcome to Iris Biotech
For better service please confirm your country and language we detected.
For better service please confirm your country and language we detected.
Thank you very much for your interest in our products. All prices listed on our website are ex-works, Germany, and may attract customs duties when imported.
You may/will be contacted by the shipping company for additional documentation that may be required by the US Customs for clearance.
We offer you the convenience of buying through a local partner, Peptide Solutions LLC who can import the shipment as well as prepay the customs duties and brokerage on your behalf and provide the convenience of a domestic sale.
Continue to Iris Biotech GmbHSend request to US distributorSynonyms: Taxol
Starting at $422.50
Paclitaxel, discovered in 1967, is a mitotic inhibitor used in cancer chemotherapy. It is used to treat patients with lung, ovarian, breast, head and neck cancer, advanced forms of Kaposi's sarcoma, and is also used for the prevention of restenosis. Paclitaxel stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division.
While offering substantial improvement in patient care, paclitaxel has been a relatively controversial drug. Side effects such as unusual bruising or bleeding, pain/redness/swelling at the injection site, change in normal bowel habits for more than two days, fever, chills, cough, sore throat, difficulty swallowing, dizziness, shortness of breath, severe exhaustion, skin rash, facial flushing, female infertility by ovarian damage and chest pain can occur.
Combination therapy is a new approach to take advantage of Paclitaxel’s anti-cancer properties and diminish its side effects. PGA (Poly(Glutamic Acid)) is an ideal carrier to be
loaded with Paclitaxel and corresponding drugs as published in the following examples:
The combination of anti-angiogenic therapy with cytotoxic one offers a promising therapeutic approach. A polyglutamic acid (PGA)-Paclitaxel-E-[c(RGDfK)2] conjugate has been developed.1,2 The combination of E-[c(RGDfK)2] with Paclitaxel in the same PGA mainchain enhanced the effects previously seen for PGA-PTX alone by utilizing: (i) the additional
active targeting to the avß3 integrin and (ii) its anti-angiogenic character. PGA-Paclitaxel-E-[c(RGDfK)2] displayed a potent anti-angiogenic therapy, revealed by several
well-established in vitro assays. Mice bearing orthotopic mammary tumors demonstrated preferential tumor accumulation of the RGD-bearing conjugate, leading to enhanced antitumor
efficacy and a marked decrease in toxicity compared with free Paclitaxel. 1,2
A. Eldar-Boock , K. Miller, J. Sanchis, R. Lupu, M.J.Vicent, R. Satchi-Fainaro. Biomaterials 2011; 132(15): 3862-74.
R. Satchi-Fainaro and M.J. Vicent; WO/2009/141826 .
Saville, M.W.; Lietzau, J.; Pluda, J.M.; Wilson, W.H.; Humphrey, R.W.; Feigel, E.; Steinberg, S.M.; Broder, S. et al. The Lancet 1995; 346(8966): 26-8.
doi:10.1016/S0140-6736(95)92654-2.
Ozcelik, Bulent; Turkyilmaz, Cagdas; Ozgun, Mahmut Tuncay; Serin, Ibrahim Serdar; Batukan, Cem; Ozdamar, Saim; Ozturk, Ahmet; Fertility and Sterility 2010; 93(5): 1609-14.
doi:10.1016/j.fertnstert.2009.02.054.
Do you need larger quantities for your development or production?
Please send me more information about